12th World Clinical Biomarkers & CDx Summit

The Apis Team will be exhibiting and speaking in person at the 12th World Clinical Biomarkers & CDx Summit in Boston, USA.

Be sure not to miss Ian Kavanagh (Chief Operating Officer & Co-Founder) talking on the ‘Development of a Novel Breast Cancer Subtyping and Proliferation Gene Expression Diagnostic Test’ in the Defining Patient Populations Track – Day 1 - 28th September @ 15:20 – 15:50 (EST).

Abstract

This talk will encompass the development of our novel ‘Breast Cancer Subtyping and Proliferation Gene Expression Diagnostic Test’:

• A RT-qPCR nucleic acid-based IVD test for the detection and relative gene expression quantification of human mRNA target genes from pre-operative CNB or resected FFPE breast tumour tissue from patients with invasive breast cancer.

• Breast cancer subtyping performance of the IVD test is determined by concordance to that assigned by the current histopathology IHC reference methodology.

• In addition to its primary clinical utility as an MDx, the potential for detection of lowly expressed ERBB2 (HER2) levels aligns the IVD test as a CDx to HER2 targeted therapies e.g. Trastuzumab deruxtecan (Enhertu).

Interested in learning more? Use this link to contact us and schedule a meeting.